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Abstract
Background: In locally advanced rectal cancer (LARC) preoperative chemoradiation (CRT) is the standard of care,
but the risk of local recurrence is low with good quality total mesorectal excision (TME), although many still
develop metastatic disease. Current challenges in treating rectal cancer include the development of effective
organ-preserving approaches and the prevention of subsequent metastatic disease.
Neoadjuvant systemic chemotherapy (NACT) alone may reduce local and systemic recurrences, and may be more
effective than postoperative treatments which often have poor compliance. Investigation of intensified NACT is
warranted to improve outcomes for patients with LARC. The objective is to evaluate feasibility and efficacy of a
four-drug regimen containing bevacizumab prior to surgical resection.
Methods/design: This is a multi-centre, randomized phase II trial. Eligible patients must have histologically confirmed
LARC with distal part of the tumour 4–12 cm from anal verge, no metastases, and poor prognostic features on pelvic
MRI. Sixty patients will be randomly assigned in a 1:1 ratio to receive folinic acid + flurourcil + oxaliplatin (FOLFOX) +
bevacizumab (BVZ) or FOLFOX + irinotecan (FOLFOXIRI) + BVZ, given in 2 weekly cycles for up to 6 cycles prior to TME.
Patients stop treatment if they fail to respond after 3 cycles (defined as ≥ 30 % decrease in Standardised Uptake Value
(SUV) compared to baseline PET/CT).
The primary endpoint is pathological complete response rate. Secondary endpoints include objective response rate, MRI
tumour regression grade, involved circumferential resection margin rate, T and N stage downstaging, progression-free
survival, disease-free survival, overall survival, local control, 1-year colostomy rate, acute toxicity, compliance to chemotherapy.
Discussion: In LARC, a neoadjuvant chemotherapy regimen - if feasible, effective and tolerable would be suitable for
testing as the novel arm against the current standards of short course preoperative radiotherapy (SCPRT) and/or
fluorouracil (5FU)-based CRT in a future randomised phase III trial.
Trial registration: Clinical trial identifier BACCHUS: NCT01650428
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Background
In LARC, preoperative chemoradiation and radiotherapy
have become accepted as the standard of care. Meta-
analyses [1] and individual trials of SCPRT [2, 3] and CRT
[4–7] have demonstrated that radiotherapy improves local
control, but provides no impact on OS [2, 3, 8]. Radiother-
apy is associated with significant late-effects [9], including
an increased risk of second malignancies [10, 11].
Recent improvements in the quality of surgery, preopera-
tive magnetic resonance imaging (MRI) and pathological
reporting, now call into question the approach of treating
all patients, clinically staged as T3, with radiotherapy or
chemoradiation to prevent local recurrence. Rather factors
that portend distant recurrence should be considered, in-
cluding tumour location and the sub-classifcation of T3,
nodal status and presence of extramural invasion. For care-
fully selected patients low rates of local recurrence can be
achieved if good quality TME is performed even when pa-
tients receive no radiotherapy [12–14]. Metastatic disease,
in contrast, is now the predominant cause of recurrence
and death. It appears a commonly held belief that any
systemic chemotherapy treatment, is likely to be more ef-
fective if administered before and not after radical surgery.
For colon cancer, systemic treatment is given postopera-
tively based on histopathogy of the surgical specimen. The
concept of neoadjuvant chemotherapy (NACT) is being
examined in primary colon cancer in the FOXTROT trial
(ISRCTN 87163246.) with promising early results [15].
For rectal cancer staging MRI can identify patients at
risk of local and/or systemic relapse preoperatively. In
particular, extramural vascular invasion (EMVI) is easily
identified on preoperative MRI, and predicts for systemic
failure with good concordance between MRI diagnosed
and eventual pathological confirmation of EMVI [16].
National Comprehensive Cancer Network (NCCN) CRC
Guidelines recommend a 6-month postoperative course of
adjuvant chemotherapy for patients with stage II/III rectal
cancer following chemoradiation [17], although this is not
evidence-based [18] and recent data suggests there is no
benefit from adjuvant 5FU apart from reducing local re-
currence [19]. Potential explanations include the difficulty
in delivering systemic chemotherapy treatment following
CRT and surgery [4–6, 20]. Consensus recommendations
suggest that decisions regarding adjuvant chemotherapy in
LARC should be dictated according to initial preoperative
clinical stage [21, 22]. Neoadjuvant chemotherapy (NACT)
has therefore been recommended as a priority of future
research, to decrease the high metastases rate [23].
Previous studies suggest tolerability and compliance
with chemotherapy in the neoadjuvant setting should be
high [24–26]. In the Grupo Cáncer de Recto 3 study
[27] NACT was delivered at full systemic doses to 94 %
of patients. In the GEMCAD 0801 study, a 15 % patho-
logical complete response (pCR) was achieved with
capecitabine + oxaliplatin (XELOX) plus BVZ [28] without
any radiotherapy.
The BACCHUS study examines whether intensive
NACT can achieve a pCR rate in primary rectal cancer
sufficient to warrant further investigation. Chemo-triplet
schedules demonstrate high response rates [29]. The
OLIVIA phase II study randomised 80 patients with
unresectable colorectal cancer liver-only metastases [30]
comparing FOLFOX plus BVZ with or without irinotecan
and reported response rates of 61.5 and 80.5 % respect-
ively with acceptable toxicity. These are the experimental
arms in BACCHUS, which will allow evaluation of the
potential benefit of BVZ in combination with modern
effective-doublet and triplet chemotherapy regimens and
omitting radiotherapy in LARC.
Methods/design
Study design
The BACCHUS trial is an investigator initiated, multicen-
tre, open-label, prospective, randomized phase II study. All
participants have to provide written informed consent,
signed and personally dated, before inclusion in the trial.
The trial EudraCT number is 2010-022754-17, and is reg-
istered on ClinicalTrials.gov (BACCHUS: NCT01650428).
Trial organisation
The sponsor is University College London. Central coord-
ination is financed by Cancer Research UK (CR UK) and
carried out by the CR UK & University College London
Cancer Trials Centre (UCL CTC). An independent data
monitoring committee (IDMC) will monitor the conduct
and safety of the trial. Participating sites are required to
report all serious adverse events (SAE) as defined by the
protocol to UCL CTC in line with applicable regulations.
Ethics and informed consent
The final protocol was approved by Riverside l Research
Ethics Committee (ref: 12/LO/1158). Appropriate ap-
proval from respective local ethics committee is required
to join this trial. This study has been approved by the eth-
ics committee of the following Hospitals or Universities:
Barnet and Chase Farm Hospital, Blackpool Teaching
Hospitals, East and North Herts Hospitals, NHS Greater
Glasgow and Clyde Hospitals, Heatherwood and Wexham
Park Hospitals, Hillingdon Hospitals, Imperial College
Healthcare NHS Trust, North Middlesex University
Hospital, The Royal Marsden Hospital, University College
Hospital, London. This study is conducted in accordance
with the most recent version of the Declaration of
Helsinki and according to GCP. Written informed con-
sent, signed and personally dated, is obtained from each
patient before inclusion in the trial.
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Population
Patients with histologically confirmed adenocarcinoma
of the rectum require specific tumour and patient
criteria for inclusion. A staging MRI is mandated. The
lists of inclusion and exclusion criteria are presented in
Tables 1 and 2.
Trial entry has been restricted to patients in whom
MRI suggest primary tumour or lymph nodes do not
extend to ≤1 mm from, or breach the circumferential
resection margin (CRM)– since even with preoperative
chemoradiation up to 30 % of these patients would have
a positive CRM (≤1 mm) after TME. Eligibility is also
confined to patients with MRI estimated penetration of
the mucularis propria >1 mm and/or patients with cN2
predicted by MRI and extramural vascular invasion
(EMVI), but T3 tumours must have a predicted ≥2 mm
margin from the mesorectal fascia.
These criteria are likely to form a group of patients
making up about 40 % of rectal cancers overall. Such
Table 1 Patient inclusion criteria
• Histologically confirmed diagnosis of adenocarcinoma of the rectum
• Distal part of the tumour within 4–12 cm of the anal verge
• No unequivocal evidence of established metastatic disease (on chest/
abdominal/pelvis CT). Patients with equivocal lesions (as determined
at MDT) are eligible
• MRI-evaluated-evaluated locally advanced tumour with the following:
• T3 tumours extending (≥4 mm), beyond the muscularis propria
N0–N2
• Or tumours (involving or threatening the peritoneal surface) or
presence of macroscopic extramural venous invasion (V2 disease)
• AND for tumours below the peritoneal reflection, the primary
tumour or involved lymph node (on MRI) must be >1 mm
from the mesorectal fascia
• Measurable disease (using RECIST criteria v1.1)
• WHO performance status 0 – 1
• In the opinion of the investigator:
▪ General condition considered suitable for radical pelvic surgery
▪ Candidate for systemic therapy with FOLFOX/FOLFOXIRI plus
bevacizumab
▪ Adequate bone marrow, hepatic and renal function:
▪ Haemoglobin ≥80 g/L
▪ ANC ≥2 × 109/L
▪ Platelet count ≥100 × 109/L
▪ ALT or AST ≤1.5 × ULN (upper limit of normal)
▪ ALP ≤1.5 × ULN
▪ Total bilirubin ≤1.5 × ULN
▪ Serum creatinine ≤1.5 × ULN
▪ Creatinine clearance ≥50 mL/min using the Cockcroft–Gault
formula (see Appendix 4). If the calculated GFR is below <50
ml/min, 51Cr-EDTA or 99mTc-DTPA clearance test must be carried
out demonstrating GFR is ≥50 ml/min
• INR ≤ 1.1
• Urine protein ≤1+ with dipstick or urine analysis.
▪ For proteinuria >1+ or urine protein/creatinine ratio ≥ 1.0, 24-h
urine protein should be obtained and the level must be <2 g
for eligibility
• No evidence of established or acute ischaemic heart disease on ECG
and normal clinical cardiovascular assessment
• No known significant impairment of intestinal absorption
• At least 18 years of age, but not more than 75 years
• Willing and able to give informed consent, comply with treatment
and follow up schedule
Table 2 Patient exclusion criteria
The following are exclusion criteria
1. Primary tumour or lymph node on MRI
• Extending <1mm from, or breaching the mesorectal fascia and
therefore the circumferential resection margin,
• Disease outside of the mesorectal envelope (internal iliac/lateral
pelvic lymph node),
2. Clinically significant cardiovascular or coronary disease ≤2 years
before randomisation,
3. History of interstitial lung disease or evidence of interstitial lung
disease on baseline chest CT scan
4. History of an arterial thromboembolic event during the previous
2 years
5. Evidence of bleeding problems or coagulopathy (Patients receiving
warfarin/coumarin derived anticoagulants at full therapeutic doses are
excluded, but prophylactic doses of 1 mg to prevent Hickman line
clotting are eligible).
6. Significant and continuing rectal bleeding leading to a haemoglobin
<80 g/L
7. Chronic use of aspirin (>325 mg/day) or clopidrogel (>75 mg/day)
within 10 days of first planned study treatment;
8. Taking phenytoin or sorivudine or its chemically related analogues,
such as brivudine
8. Patients requiring regular use of anti-diarrhoeal medication; (NB
Patients with ileostomy will not be able to participate if they require
regular use of anti-diarrhoeal agents)
9. Serious uncontrolled intercurrent illness including poorly controlled
diabetes mellitus;
10. Metallic colonic or rectal stent in situ
11. Previous pelvic radiotherapy;
12. Previous treatment with another investigational agent within 30 days
prior to randomisation;
13. Patients with a history of previous malignancy in the past 5 years,
excepting basocellular or squamous cell skin cancer, or properly
treated cervicouterine cancer in situ;
14. Known HIV, HBV or HCV infection;
15. Pregnant or lactating women or pre-menopausal women not using
adequate contraception;
16. Current smoker, or clinically relevant history of drug or alcohol
abuse;
17. Patients with any other condition or concurrent medical or
psychiatric disease who, in the opinion of the investigator,
are not eligible to enter the study.
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patients have a 50 % 5 year survival [32] and a local
recurrence rate of 6–10 % with surgery alone.
Trial entry has also been restricted to patients younger
than 70 years with distal rectal tumours, 4–12 cm from
the anal verge. Accurate clinical staging with MRI is
more diffcult in the low rectum, at lower than 4 cm
there is a 5–15 % risk of involved lateral pelvic lymph
nodes, which are not resected at TME. A lack of
evidence to suggest a benefit from oxaliplatin containing
adjuvant chemotherapy for stage II colorectal cancer
[34–36] and insufficient data to support a benefit from
adjuvant chemotherapy in Stage III colorectal cancer in
patients over 70 years has informed the decision to
exclude patients over 70 years from this trial [33].
Study objectives and endpoints
The primary objective of the BACCHUS study is to
evaluate the efficacy of FOLFOXIRI + BVZ and FOL-
FOX + BVZ in terms of their ability to produce pCR.
Secondary objectives include evaluation of the safety and
tolerability of the two regimes and the feasibility of de-
livering them, as well assessment of additional measures
of efficacy such as progression free and overall survival.
The primary endpoint is pathological complete response
(pCR) at surgery; secondary endpoints include ORR, CRM
negative (R0) resection rate, T and N stage downstaging,
PFS, DFS, OS, local control, 1 year colostomy rate, adverse
events, compliance with chemotherapy treatment, tumour
regression grade (TRG), and tumour cell density (TCD).
Survival curves for DFS and OS will be plotted. Cumula-
tive incidence of local recurrence will be computed
accounting for death as competing risk. Differences in sur-
vival will be tested with the log-rank test. Hazard ratios
and 95 % confidence intervals (CI) will be computed using
Cox regression. A table will present the completion rate of
the neo-adjuvant treatment, pCR frequency, patients with
a R0 resection with 90 and 95 % CI. Frequency and
percentages for toxicity will be presented according to the
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0. All proportions will be presented
with 95 % CI.
Randomisation and stratification
Patient Randomisation will be performed centrally at the
UCL trials centre. Eligible patients are randomly assigned
to one of the two treatment arms in a 1:1 ratio and strati-
fied according to treating centre, gender and presence or
absence of EMVI. Treatment process and schedules for
the BACCHUS trial are summarised in Figs. 1 and 2.
Neoadjuvant Chemotherapy
In both arms, chemotherapy is delivered with bevacizu-
mab. In total, 6 cycles of chemotherapy are prescribed
preoperatively every 2 weeks (bevacizumab omitted
during cycle 6). Adverse events are monitored from
informed consent to 3 months after surgery and dose
modification can be made according to specified proto-
col guidelines.
Assessments/follow up
Response and resectabilty evaluation
Clinical response has not been shown to be a robust
surrogate endpoint to predict outcome. However, pa-
tients will undergo response evaluation with MRI of the
pelvis prior to cycle 4 and at the end of all treatment
(prior to surgery) according to the Response Evaluation
Criteria in Solid Tumours (RECIST 1.1) and additionally
MRI-based TRG assessment is required [37]. An add-
itional response evaluation according to standard uptake
values (SUV) changes with PET/CT is mandated prior
to cycle 4. Patients who do not respond will come off all
trial treatment (allowing the investigator to proceed to
whatever treatment is felt most appropraite ie surgery or
SCPRT/CRT followed by surgery).
Tolerability to treatment is evaluated at each visit
including physical examination, vital signs, WHO per-
formance status, clinical laboratory profile, and adverse
events, graded according to NCI-CTCAE v.4.03.
Surgery and histopathology
Surgery should be performed 8–12 weeks after ter-
mination of chemotherapy, and a minimum of 8 weeks
after the final dose of bevacizumab. Surgical dissec-
tion according to TME principles should not differ
between the two trial groups and can be performed
open or laparoscopically. Surgery may include anterior re-
section, abdominoperineal resection or a low Hartmann’s
procedure.
Pathological evaluation of resected specimens will be
according to guidelines included in the study protocol.
The 5th edition of TNM will be used. In addition,
circumferential resection margin (CRM) will be assessed
and a margin of 1 mm or less considered positive. TRG
will be presented as data categorised into five groups-
TRG 0, TRG 1, TRG 2, TRG 3 and TRG 4 using the
Dworak method. Also, the quality of the resected speci-
men will be evaluated with separate scoring for the mesor-
ectum and the anal canal. Formalin fixed and paraffin
embedded (FFPE) tumour tissue obtained at baseline will
be evaluated for KRAS and BRA status and plasma /buffy
coat collected at baseline and before the 2nd, 3rd and the
4th cycle (and also if the patient relapses), will be assessed
for angiogenic markers (FFPE and serum) in the
BACCHUS trial. Serum obtained at baseline, during
preoperative treatment, postoperatively and at follow up
will be evaluated for circulating tumour DNA.
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Fig. 1 Treatment schedule
Fig. 2 The BACCHUS trial. Patients will be randomised to one of two neoadjuvant chemotherapy regimens
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Adjuvant chemotherapy and follow-up
Patients can be treated with postoperative chemotherapy
according to the local protocol of each participating centre.
Patients will be followed up every 6 months for up to
42 months after randomisation, to document progression,
recurrence and survival. Postoperative investigations/sur-
veillance are performed according to local practice.
Statistical considerations and sample size estimation
The primary endpoint for this trial is the pCR of the
TME specimen. The proportion of patients in each arm
who achieve a pCR will be presented, along with a 95 %
CI. Within each group the achieved pCR rate will be
compared to the historical rate achieved by radiotherapy
alone (5 %). In the United Kingdom patients without a
threat to the circumferential resection margin are likely
to be treated with short course preoperative RT, and not
chemoradiation. The study is powered on the assump-
tion that a proportion of patients will have a pCR. It is
well recognised that patients who have a complete
clinical response (cCR) both on imaging and clinical
examination will from time to time refuse surgery. For
the purpose of this study, patients who have a sustained
cCR at 12 months will be considered the same as a
patient with a complete pathological response. Patients
with a transient clinical response where subsequent re-
lapse is observed within this 12 month period, will not.
Based on pCR with similar regimens prior to liver re-
section, and primary tumours responding better than
metastases, we anticipate a pCR rate of 15–20 %. Com-
pared to 5 % pCR rate historically for radiotherapy alone,
a type I error α =0.05 and a type I I error β =0.8, 27 pa-
tients for the FOLFOX arm are required. The same
number of patients is required for the FOLFOXIRI arm.
Assuming 10 % of patients will be non-evaluable, 30
patients will be recruited to each arm (i.e. a total of 60
patients. NACT will be considered worth exploring
further in a randomised phase III trial if at least 4/27
pCRs are observed. In the instance of more than 27
patients being assessed for pCR, the first 27 randomised
patients per arm will be assessed. The study is not pow-
ered for a direct comparison between the two arms.
Quality assurance/safety
Monitoring will be conducted centrally at UCL CTC
and on-site monitoring will be scheduled if there is any
evidence of non-compliance at site. An independent data
safety monitoring committee (IDMC) meeting will be
held periodically to review interim analysis, or as neces-
sary to address any issues.
Translational research
Analyses of both tumour tissue and plasma with tissue
microarray, proteomics and genomics may generate
increased knowledge of prognosis and prediction of re-
sponse to chemotherapy in the BACCHUS trial. Hence,
a schedule for collection of plasma and of fresh tissue
for freezing, at different stages of treatment in each arm,
is defined in the study protocol.
Tumour tissue and blood samples will be stored for
future research. At surgical resection blocks of tumour
and normal mucosa will be also be collected. In addition,
H&E stained slides from the diagnostic biopsy and resec-
tion samples will be collected to undertake Tumour Cell
Density and Tumour regression Grading.
Plasma and Peripheral Blood Leucocytes (PBL) samples
will be collected at baseline and at the following time-
points during treatment :-Baseline (prior to starting treat-
ment cycle 1), prior to starting treatment cycle 2, prior to
starting treatment cycle 3, prior to starting treatment cycle
4 (preferably at radiological response assessment) and if
patient relapses.
Conventional size–based radiological criteria using
RECIST may not be the optimal method of assessing
response to chemotherapy, especially with a regimen inte-
grating bevacizumab) [37, 38]. Hence, imaging biomarkers
will also be explored in terms of mri-based TRG and MRI
diffusion weighted imaging [39]. Exploratory SPECT
imaging using Tc99m-maraciclitide as the tracer in a
subset of patients at baseline and post treatment will
provide information regarding changes in angiogenesis
with treatment.
Discussion
Why have we chosen to use bevacizumab?
Solid tumours are characterised by changes in structural
architecture, which forms a barrier to uptake and penetra-
tion of cytotoxic drugs [40] and engenders hypoxia.
Bevacizumab, a recombinant humanized monoclonal anti-
body against vascular endothelial growth factor (VEGF),
increases response rates in metastatic colorectal cancer
when combined with fluoropyrimidine-based regimen.
When given neoadjuvantly, a VEGF inhibitor may act to
prevent vessel formation and thus establishment of distant
micrometastases.
In a non-randomised study comparing FOLFOXIRI
and the four-drug intensive regimen combining FOL-
FOXIRI + BVZ in patients with liver metastases, 63 % of
patients treated with FOLFOXIRI+ BVZ, versus 28 %
treated with FOLFOXIRI/XELOXIRI alone, showed a
histopathological response (P = 0.033) [41].
The BACCHUS study explores the use of bevaizumab
in LARC with only potential loco-regional spread, which
to some extent should limit evolutionary diversity in the
tumour, and hopefully enhance response. All three adju-
vant trials testing the role of bevacizumab; QUASAR,
AVANT and CO8 excluded rectal cancer, because of the
confounding issue of radiotherapy [42, 43] yet recent
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retrospective analysis of a cohort of 667 consecutive
patients with metastatic colorectal cancer showed that
patients treated with capecitabine, oxaliplatin and
bevacizumab in whom the primary tumour originates in
the rectum and/or sigmoid colon had better outcomes
than patients with right-sided primary tumours [44]. Tu-
mours in the distal colon and rectum also have higher
expression of VEGF A (a hypothetical target of bevacizu-
mab) than those in the proximal colon [45]. If there is
an interaction between the location of the primary
tumour and the effectiveness of antiangiogenic agents,
future studies should stratify for the precise location of
the primary tumour.
There is a consistently reported problem with delivery of,
and compliance with chemotherapy following preoperative
SCPRT or CRT and surgery. The EORTC 22921 trial
showed compliance to postoperative adjuvant chemother-
apy was very poor at 42.9 %. At least 25 % of patients in
whom chemotherapy might be considered may not be
sufficiently fit for treatment or decline [5, 6, 19]. The
Chronicle trial highlighted this difficulty [46].
Neoadjuvant chemotherapy for locally advanced
rectal cancer
In locally advanced rectal cancer, the NSABP-R03 study
employed a weekly schedule of 5FU and folinic acid for
six weeks prior to definitive preoperative chemoradia-
tion. A response rate of 44 % was achieved in the first
39 patients who completed all 6 cycles [7, 47]. Only 2
patients (5 %) progressed on this regimen. In a phase II
study using neoadjuvant capecitabine and oxaliplatin, the
clinical response rate was 88 % and no patient progressed
radiologically [25]. Hence, anxieties that patients will pro-
gress on neoadjuvant chemotherapy appear unfounded.
The culture is now changing slowly away from the
routine or blanket use of radiotherapy. The GEMCAD
0801 study achieved a 15 % pCR with XELOX + BVZ in
[28] in a population very similar to those intended to be
recruited into BACCHUS and without any radiotherapy.
The Tribe study [31] showed a high clinical response
rate in both arms - viz 53 % for FOLFOX + BVZ versus
65 % FOLFOXIRI + BVZ, with Grade 3 diarrhoea man-
ageable at 9 and 19 % respectively.
Induction Bevacizumb and FOLFOXIRI has been
shown to be a feasible regimen with acceptable toxicity
(mainly neutropenia) in a multicentre study [49]. The
ongoing Italian Trust study aims to treat 43 patients
with LARC using FOLFOXIRI + BVZ followed by cape-
citabine based chemoradiation with bevacizumab. To
date 23 patients have been randomised with a PCR of
38 %, and only 7 % surgical morbidity [52].
Our results should be better than the Tribe study since
previous adjuvant chemotherapy impacted negatively on
response in the FOLFOXIRI + BVZ arm. In BACCHUS,
because the chemotherapy is neoadjuvant, patients will be
chemotherapy naive. Since patients do not have metastatic
disease, response rates for both arms should be even
higher – probably in the region of 90 % since in the
EXPERT C study XELOX and XELOX and cetuximab
provided clinical response rates of 64 and 54 % respect-
ively overall, and 71 % versus 51 % for patients expressing
wild type KRAS [49].
Limitations
The design of the BACCHUS trial has been criticised
because, due to safety reasons and because patients over
70 years with stage II rectal cancer disease do not appear
to benefit from adjuvant chemotherapy – particularly
with oxaliplatin [33, 38]. Despite patients with rectal
cancer across Europe having a median age at presentation
of 71 years, an upper age limit of 70 years is mandated in
BACCHUS because of these safety and futility concerns.
The median age in most chemotherapy metastatic trials is
65 and the median age in most chemoradiation studies is
63 years [4–7, 50].
BACCHUS focuses on the efficacy and feasibility of
preoperative FOLFOXIRI+ BVZ . The randomised design
was chosen (albeit inevitably limited by the small number
of patients) to compare efficacy in terms of pathological
complete response and acute toxicity, in order to
demonstrate the feasibility of avoiding radiation in
this group of patients.
Neoadjuvant chemotherapy without chemoradiation
Neo-adjuvant chemotherapy may achieve better access
to malignant cells when the tumour has an intact blood
supply, and offer better compliance to treatment [27]
unlike an adjuvant approach which has failed to show
any overall survival benefit in rectal cancer. Given
neoadjuvantly, systemic doses of chemotherapy can be
delivered at an earlier stage of disease rather than the
delay of up to 18 weeks associated with standard CRT plus
surgery. Two studies from the Memorial Sloan-Kettering
Cancer Center (MSKCC) support the feasibility of neoad-
juvant chemotherapy alone in rectal cancer [51, 52]. This
feasibility study in patients with clinical stage II-III rectal
cancer (but not T4 tumours) used FOLFOX + BVZ [52].
The R0 resection rate was the primary outcome. They
reported a pCR in 8/29 patients (27 %). BACCHUS is a
corroborative feasibility study but assessing more intensive
chemotherapy in one arm. Based on the MSKCC results, a
large multicentre Phase II/III study is currently accruing
patients. In this CALGB PROSPECT/Allianz N1048 trial,
patients are randomised to either 5FU-based chemo-
radiotherapy, surgery, and adjuvant FOLFOX chemo-
therapy, or the novel selective arm treating with 6 cycles
of FOLFOX neoadjuvant chemotherapy and surgery alone.
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The primary endpoints of the Phase III components are
time to local recurrence and disease-free survival.
Two small Japanese NACT studies have also dem-
onstrated the feasibilty of this NACT approach and
have included bevacizumab [53, 54]; there is a sugges-
tion of increased surgical morbidity, but the rectal tu-
mours were situated lower, on average 4.7 cm from
anal verge, than those we hope to include in the
BACCHUS study and surgery was performed earlier
than specified in BACCHUS (3–8 versus 8–12 weeks)
A higher dose of Bevacizumab was administered ie
7.5 mg/kg in these studies- in contrast to BACCHUS
where the dose is 5 mg/Kg.
Finally the Olivia trial [30] used FOLFOXIRI and
bevacizumab neoadjuvantly, in patients with mCRC
deemed resectable and were offered surgery 5–7 weeks
after their last bevacizumab dose and 3–5 weeks after
their last chemotherapy cycle, a similar surgical timing of
the 8–12 weeks mandated in BACCHUS.
The BACCHUS trial will therefore evaluate the
efficacy of an intensive versus a standard first-line
chemotherapy combination both with bevacizumab in
patients with locally advanced/high risk rectal cancer
to examine local control and long-term disease
outcomes. Treatment duration is limited to a max-
imum of 3 months FOLFOXIRI + BVZ versus FOL-
FOX + BVZ.
PCR was chosen as the primary endpoint to confirm
non-inferiority regarding the comparative efficacy with
the standard chemoradiation option for these patients as
this will then allow more confident treatment decisions
to exclude radiotherapy for such patients in the future.
Histopathological response is considered as a useful
endpoint after chemotherapy for metastatic colorectal
cancer (mcrc), representing a marker of sensitivity to
preoperative treatments and a prognostic factor asso-
ciated with longer survival [55, 56]. Although we are
hoping in time to show that a neoadjuvant approach
may influence overall survival, perhaps via biological/
microenvironmental mechanisms surrounding micro-
metastases when a primary remains in situ, in con-
trast to adjuvant therapy,
In BACCHUS we are testing the feasibility of bevaci-
zumab in a neoadjuvant setting where bleeding and
perforation could prejudice the performance and qual-
ity of surgery. If the phase 2 passes tests of efficacy,
safety and feasibility, we plan to develop a phase III
study. Potential designs include, 3 months of neoadju-
vant chemotherapy prior to surgery, followed by the
option for a further 3 months of postoperative chemo-
therapy randomised against initial surgery followed by
6 months of postoperative adjuvant chemotherapy ac-
cording to histology or alternatively against the current
standard of SCPRT or chemoradiation.
Conclusions
The BACCHUS trial will give further information
about the feasibility, safety, tolerability and benefit of
neoadjuvant FOLFOX or FOLFOXIRI + BVZ in this
distinct disease setting of locally advanced but clearly
resectable rectal cancer.
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